Magwate, Rayza L.
HRN: 22-45-16 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/05/2023
OXACILLIN 500MG (VIAL)
01/05/2023
01/12/2023
IV
275mg
Q6hours
URTI; Anemia, Severe
Waiting Final Action
Indication: Empiric Type of Infection: URTISkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes